Iron Triangle Partners LP Cuts Holdings in Insulet Corporation $PODD

Key Points

• Iron Triangle Partners LP has reduced its stake in Insulet Corporation by 31.2%, now holding 106,029 shares worth approximately $27.8 million.
• Several hedge funds have increased their positions in Insulet, with MassMutual Private Wealth & Trust FSB leading with a 23.1% increase.
• Insulet's stock received positive ratings from multiple research firms, with Canaccord Genuity raising its price target from $331 to $353 and maintaining a "buy" rating.

Iron Triangle Partners LP cut its position in Insulet Corporation (NASDAQ:PODD - Free Report) by 31.2% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 106,029 shares of the medical instruments supplier's stock after selling 47,985 shares during the quarter. Insulet accounts for about 4.4% of Iron Triangle Partners LP's portfolio, making the stock its 8th largest holding. Iron Triangle Partners LP owned about 0.15% of Insulet worth $27,844,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Brooklyn Investment Group raised its position in shares of Insulet by 7.0% in the 1st quarter. Brooklyn Investment Group now owns 795 shares of the medical instruments supplier's stock valued at $209,000 after buying an additional 52 shares in the last quarter. OLD National Bancorp IN grew its holdings in shares of Insulet by 6.7% during the 1st quarter. OLD National Bancorp IN now owns 880 shares of the medical instruments supplier's stock valued at $231,000 after purchasing an additional 55 shares during the last quarter. Cooper Financial Group grew its holdings in shares of Insulet by 5.7% during the 1st quarter. Cooper Financial Group now owns 1,079 shares of the medical instruments supplier's stock valued at $283,000 after purchasing an additional 58 shares during the last quarter. MassMutual Private Wealth & Trust FSB grew its holdings in shares of Insulet by 23.1% during the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 314 shares of the medical instruments supplier's stock valued at $82,000 after purchasing an additional 59 shares during the last quarter. Finally, HighTower Advisors LLC grew its holdings in shares of Insulet by 2.1% during the 1st quarter. HighTower Advisors LLC now owns 2,882 shares of the medical instruments supplier's stock valued at $757,000 after purchasing an additional 60 shares during the last quarter.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on PODD shares. Barclays lifted their price target on shares of Insulet from $266.00 to $300.00 and gave the company an "equal weight" rating in a report on Thursday, August 21st. Canaccord Genuity Group lifted their price target on shares of Insulet from $331.00 to $353.00 and gave the company a "buy" rating in a report on Friday, August 8th. The Goldman Sachs Group started coverage on shares of Insulet in a report on Friday, May 30th. They set a "buy" rating and a $380.00 price target on the stock. Sanford C. Bernstein reaffirmed an "outperform" rating on shares of Insulet in a report on Friday, May 16th. Finally, Jefferies Financial Group reiterated a "buy" rating on shares of Insulet in a research report on Thursday, August 7th. Sixteen investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, Insulet presently has an average rating of "Moderate Buy" and an average target price of $332.71.

Insulet Trading Up 1.5%

Insulet stock traded up $5.03 during mid-day trading on Tuesday, hitting $344.91. 633,445 shares of the stock were exchanged, compared to its average volume of 755,949. The firm's fifty day simple moving average is $304.69 and its two-hundred day simple moving average is $288.12. Insulet Corporation has a 12 month low of $199.68 and a 12 month high of $350.00. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64. The stock has a market capitalization of $24.28 billion, a price-to-earnings ratio of 104.84, a PEG ratio of 2.85 and a beta of 1.36.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 EPS for the quarter, topping the consensus estimate of $0.92 by $0.25. The company had revenue of $649.10 million during the quarter, compared to the consensus estimate of $612.31 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The company's quarterly revenue was up 32.9% on a year-over-year basis. During the same quarter last year, the firm posted $0.55 EPS. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Analysts forecast that Insulet Corporation will post 3.92 EPS for the current year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.